BRPI0802241A2 - células-tronco mesenquimais e seus usos - Google Patents

células-tronco mesenquimais e seus usos Download PDF

Info

Publication number
BRPI0802241A2
BRPI0802241A2 BRPI0802241-0A BRPI0802241A BRPI0802241A2 BR PI0802241 A2 BRPI0802241 A2 BR PI0802241A2 BR PI0802241 A BRPI0802241 A BR PI0802241A BR PI0802241 A2 BRPI0802241 A2 BR PI0802241A2
Authority
BR
Brazil
Prior art keywords
stem cells
mesenchymal stem
animal
promotes
fibrosis
Prior art date
Application number
BRPI0802241-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Sudeepta Aggarwal
Mark F Pittenger
Timothy Varney
Alla Danilkovitch
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Publication of BRPI0802241A2 publication Critical patent/BRPI0802241A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
BRPI0802241-0A 2007-03-22 2008-03-21 células-tronco mesenquimais e seus usos BRPI0802241A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/726,676 US20080095749A1 (en) 2004-03-22 2007-03-22 Mesenchymal stem cells and uses therefor
PCT/US2008/057828 WO2008116157A2 (en) 2007-03-22 2008-03-21 Mesenchymal stem cells and uses therefor

Publications (1)

Publication Number Publication Date
BRPI0802241A2 true BRPI0802241A2 (pt) 2011-08-30

Family

ID=39735516

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0802241-0A BRPI0802241A2 (pt) 2007-03-22 2008-03-21 células-tronco mesenquimais e seus usos

Country Status (10)

Country Link
US (3) US20080095749A1 (enExample)
EP (6) EP4438721A3 (enExample)
JP (2) JP2010522212A (enExample)
KR (7) KR20160027230A (enExample)
CN (1) CN101626772A (enExample)
BR (1) BRPI0802241A2 (enExample)
CA (2) CA3134185A1 (enExample)
DK (1) DK2123747T3 (enExample)
ES (3) ES2765650T3 (enExample)
WO (1) WO2008116157A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298863B1 (en) 2004-03-22 2015-07-22 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
EP1729788B1 (en) * 2004-03-30 2009-11-25 Boston Scientific Limited Restenosis therapy using mesenchymal stem cells
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
DK1926813T4 (da) 2005-09-23 2019-08-19 Tigenix S A U Cellepopulationer med immunregulatorisk aktivitet, fremgangsmåde til isolering og anvendelser
EP1957633B1 (en) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
EP2471903B1 (en) 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
CA2893204C (en) 2006-01-13 2016-11-29 Alla Danilkovitch Mesenchymal stem cells expressing tnf-.alpha. receptors
PL2120977T3 (pl) 2007-02-12 2013-12-31 Anthrogenesis Corp Leczenie chorób zapalnych z zastosowaniem łożyskowych komórek macierzystych
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
WO2009134429A2 (en) * 2008-05-02 2009-11-05 Massachusetts Institute Of Technology Methods and compositions for modulating immunological tolerance
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
EP3172963B1 (en) 2008-08-20 2019-02-06 Celularity, Inc. Improved cell composition and methods of making the same
DK2331109T3 (da) 2008-08-22 2013-09-08 Anthrogenesis Corp Fremgangsmåder og sammensætninger til behandling af knogledefekter med placentale cellepopulationer
BRPI0919804A8 (pt) * 2008-10-05 2016-10-11 Friedlander Hymie Métodos e composição para o tratamento de problemas dermatológicos e/ou condições de cabelo
RU2562154C2 (ru) 2008-11-19 2015-09-10 Антродженезис Корпорейшн Амниотические адгезивные клетки
EP3831930A1 (en) * 2009-07-21 2021-06-09 ABT Holding Company Use of stem cells to reduce leukocyte extravasation
WO2011070974A1 (ja) * 2009-12-07 2011-06-16 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
CA2784847C (en) * 2009-12-18 2017-11-21 Molly Sandra Shoichet Injectable polymer composition for use as a cell delivery vehicle
EP2555783A1 (en) 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
KR101677293B1 (ko) * 2010-04-16 2016-11-17 서울대학교병원 줄기세포의 활성을 증가시키는 방법 및 상기 방법에 의해 제조된 고활성 줄기 세포
EP2568991B3 (en) 2010-05-12 2018-11-28 ABT Holding Company Modulation of splenocytes in cell therapy
EP4663241A2 (en) 2010-10-08 2025-12-17 Mesoblast International Sàrl Enhanced msc preparations
CN101991880A (zh) * 2010-11-08 2011-03-30 中国人民解放军军事医学科学院基础医学研究所 由复合msc的plga/tcp和msc组成的制剂及其应用
CN101991878A (zh) * 2010-11-08 2011-03-30 中国人民解放军军事医学科学院基础医学研究所 由复合msc的plga和msc组成的制剂及其应用
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
WO2012125471A1 (en) * 2011-03-11 2012-09-20 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
US9040035B2 (en) 2011-06-01 2015-05-26 Anthrogenesis Corporation Treatment of pain using placental stem cells
TWI698242B (zh) 2011-11-30 2020-07-11 安斯泰來再生醫藥協會 利用血管母細胞產生間葉基質細胞之方法
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CN103191154B (zh) * 2012-01-06 2015-09-09 上海交通大学医学院 充质干细胞及其提取方法在制备银屑病的药物中的应用
WO2014098960A2 (en) * 2012-05-16 2014-06-26 The Johns Hopkins University Stem cells as an individualized maternal therapy for prevention of prematurity
US9745551B2 (en) 2012-07-12 2017-08-29 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CN105358163B (zh) * 2012-12-12 2020-09-11 麦瑟布莱斯特公司 内皮功能障碍和炎症的疾病的治疗
AU2013360026B2 (en) * 2012-12-12 2018-06-21 Mesoblast, Inc. Methods of treating or preventing respiratory conditions
NZ629700A (en) * 2012-12-24 2017-01-27 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
EP2970914B1 (en) * 2013-03-13 2019-07-03 The University of Queensland A method of isolating cells for therapy and prophylaxis
EP3795159A1 (en) 2013-04-12 2021-03-24 Houston Methodist Hospital Improving organs for transplantation
US20160120910A1 (en) * 2013-06-25 2016-05-05 Tigenix S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US20160245825A1 (en) * 2013-10-04 2016-08-25 Cell Ideas Pty Ltd Biomarkers for Cell Therapy
JP6210049B2 (ja) 2014-11-04 2017-10-11 トヨタ自動車株式会社 車両
US20180000969A1 (en) * 2015-01-08 2018-01-04 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat)
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
CA2983950A1 (en) * 2015-04-24 2016-10-27 Tigenix S.A.U. Biomarkers for determining the clinical response to cell therapy
JP6824994B2 (ja) 2015-10-07 2021-02-03 サングイ バイオ ピーティーワイ． エルティーディー 血液の調製及びプロファイリング
AU2016374643B2 (en) * 2015-12-22 2023-12-14 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
CN105769911A (zh) * 2016-03-23 2016-07-20 中国人民解放军第二军医大学 间充质干细胞诱导斑秃处毛发再生的方法及应用
KR101970642B1 (ko) * 2016-04-06 2019-05-17 주식회사 제이제이메이딘 줄기세포 배양용 배지조성물 및 그를 이용한 줄기세포 배양방법
JP7108537B2 (ja) * 2016-04-27 2022-07-28 ロート製薬株式会社 Ｃｄ２０１、ｃｄ４６、ｃｄ５６、ｃｄ１４７及びｃｄ１６５からなる群より選択される少なくとも１種の細胞表面マーカーを発現する間葉系幹細胞及びその調製方法、並びに上記間葉系幹細胞を含む医薬組成物及びその調製方法
JP6882450B2 (ja) 2016-08-05 2021-06-02 株式会社エキソステムテックＥｘｏｓｔｅｍｔｅｃｈ Ｃｏ．，Ｌｔｄ． 脂肪由来幹細胞から抽出されたエキソソームを有効成分として含む肺線維症の予防または治療用の組成物
WO2018092769A1 (ja) 2016-11-15 2018-05-24 株式会社カネカ 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN106492194A (zh) * 2016-11-30 2017-03-15 广州赛莱拉干细胞科技股份有限公司 一种干细胞外泌体制剂及其制备方法和应用
WO2018112500A1 (en) 2016-12-20 2018-06-28 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors
WO2018151046A1 (ja) * 2017-02-15 2018-08-23 ロート製薬株式会社 肺線維症治療剤、ｐｔｐｒｒ発現促進剤及び肺線維症治療用キット
ES2977897T3 (es) 2017-03-15 2024-09-02 Orca Biosystems Inc Composiciones y métodos para trasplantes de células madre hematopoyéticas
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
JP7454379B2 (ja) 2017-12-28 2024-03-22 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
CN112566644A (zh) * 2018-07-17 2021-03-26 北京三有利和泽生物科技有限公司 牙源干细胞及其用途
US20220154147A1 (en) * 2019-03-12 2022-05-19 Global Stem Cell Technology Immunomodulating mesenchymal stem cells
WO2020190094A1 (ko) * 2019-03-21 2020-09-24 (주)안트로젠 중간엽줄기세포-하이드로겔을 함유하는 주사형 조성물 및 이의 제조, 동결 및 해동방법
JP7530893B2 (ja) 2019-06-14 2024-08-08 株式会社カネカ 間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法
CN110772537A (zh) * 2019-11-07 2020-02-11 深圳科康干细胞技术有限公司 脐带血间充质干细胞组合物在治疗慢性阻塞性肺疾病中的应用
CN115361958A (zh) * 2020-03-05 2022-11-18 迈索布拉斯特国际有限公司 使用间充质谱系前体或干细胞治疗炎症性肺病的方法
WO2021198454A1 (en) * 2020-04-03 2021-10-07 Mesoblast International Sàrl Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
US20210315937A1 (en) * 2020-04-08 2021-10-14 University Of South Florida Methods of treating inflammation
AU2021267900A1 (en) 2020-05-08 2023-01-19 Gallant Pet Inc. Uterine-derived regenerative cell compositions and uses thereof
EP3909594A1 (en) * 2020-05-14 2021-11-17 Bernat Soria Escoms Mesenchymal stromal cells for the treatment of covid-19 and other inflammatory, autoimmune and degenerative diseases
CN111568930A (zh) * 2020-05-23 2020-08-25 湖南源品细胞生物科技有限公司 一种msc用于调节nk细胞数量的应用
JP7691488B2 (ja) * 2020-07-20 2025-06-11 ブレインストーム セル セラペウティクス リミテッド 肺疾患を治療するための方法及び組成物
CN112076217A (zh) * 2020-10-26 2020-12-15 重庆医科大学附属第一医院 一种间充质干细胞来源的抗炎症氧化脂质组合物的制备方法
AU2023323861A1 (en) * 2022-08-11 2025-02-27 Boehringer Ingelheim Vetmedica Gmbh Mesenchymal stem cells for use in the treatment of insect-bite hypersensitivity in equines
CN117398450B (zh) * 2023-10-31 2025-03-11 北京三有利和泽生物科技有限公司 过表达肝细胞生长因子的间充质干细胞在制备哮喘药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5843425A (en) * 1992-02-19 1998-12-01 The General Hospital Corporation Transplantation and graft-versus-host-disease
CA2109729A1 (en) * 1992-03-23 1993-09-30 James G. Bender In vitro-derived human neutrophil precursor cells
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6077987A (en) * 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
JP4441115B2 (ja) * 1998-03-13 2010-03-31 オシリス セラピューティクス，インコーポレイテッド ヒト非自己間葉幹細胞を使用する方法と利用
US6328960B1 (en) * 1998-03-18 2001-12-11 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
DE69910362T2 (de) * 1998-04-03 2004-06-24 Osiris Therapeutics, Inc. Anwendung der mesenchymalen stammzellen als immunsuppressiva
US6835377B2 (en) * 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
BR9912662A (pt) * 1998-07-31 2001-06-05 Genzyme Corp Melhoria de função cardìaca por transplante de célula de ramo mesenquimal
CA2429502A1 (en) * 2000-07-26 2002-01-31 Scimed Life Systems, Inc. Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
US20020045260A1 (en) * 2000-10-17 2002-04-18 Shih-Chieh Hung Method of isolating mesenchymal stem cells
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
JP2006502085A (ja) * 2002-01-14 2006-01-19 ヘンリー・フオード・ヘルス・システム 血管の形成ならびに血管新生および栄養因子の生産に使用するための骨髄間質細胞に由来する物質
US6974991B2 (en) * 2003-10-29 2005-12-13 International Business Machines Corp. DRAM cell with buried collar and self-aligned buried strap
EP2298863B1 (en) * 2004-03-22 2015-07-22 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
JP4326462B2 (ja) * 2004-11-19 2009-09-09 富士通株式会社 半導体集積回路の設計を支援する設計支援装置、設計支援プログラム、及び設計支援方法
WO2006112365A1 (ja) * 2005-04-14 2006-10-26 Japan Health Sciences Foundation 間葉系幹細胞を用いる肺気腫の治療
TWM290409U (en) * 2005-10-14 2006-05-11 Ming Shiau Retractable barbeque rack
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
CA2705450A1 (en) * 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al Stem cells for treating lung diseases
US8029805B2 (en) 2008-07-25 2011-10-04 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Recombinant B. pseudomallei adhesin protein and methods and uses thereof

Also Published As

Publication number Publication date
CA2637157A1 (en) 2008-09-21
US20090220464A1 (en) 2009-09-03
US20080095749A1 (en) 2008-04-24
ES2988291T3 (es) 2024-11-20
KR20160027230A (ko) 2016-03-09
KR20220018084A (ko) 2022-02-14
KR102357942B1 (ko) 2022-02-03
EP3973970B1 (en) 2024-08-28
DK2123747T3 (en) 2016-07-04
WO2008116157A2 (en) 2008-09-25
EP4438721A2 (en) 2024-10-02
KR20190031346A (ko) 2019-03-25
EP2051718A2 (en) 2009-04-29
EP4438721A3 (en) 2025-04-02
KR20250052468A (ko) 2025-04-18
JP5961220B2 (ja) 2016-08-02
HK1136601A1 (en) 2010-07-02
CA3134185A1 (en) 2008-09-21
EP3095450A1 (en) 2016-11-23
EP3095450B1 (en) 2019-10-23
EP3973970A1 (en) 2022-03-30
KR20240008404A (ko) 2024-01-18
ES2765650T3 (es) 2020-06-10
JP2014224117A (ja) 2014-12-04
US20100330048A1 (en) 2010-12-30
EP3653217A1 (en) 2020-05-20
KR20220166876A (ko) 2022-12-19
KR102519603B1 (ko) 2023-04-10
KR20090122415A (ko) 2009-11-30
CN101626772A (zh) 2010-01-13
ES2891574T3 (es) 2022-01-28
JP2010522212A (ja) 2010-07-01
WO2008116157A3 (en) 2009-03-19
EP3653217B1 (en) 2021-09-08
EP2123747A1 (en) 2009-11-25
EP2123747B1 (en) 2016-06-08
CA2637157C (en) 2021-11-23

Similar Documents

Publication Publication Date Title
BRPI0802241A2 (pt) células-tronco mesenquimais e seus usos
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
WO2008042174A3 (en) Mesenchymal stem cells and uses therefor
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
BR112013005300A2 (pt) composições que compreendem extratos ácidos da goma mástique
BR112013000537A2 (pt) composição aquosa contendo bromexina
BR112016006926A2 (pt) composições compreendendo um conjugado de ácido quínico com ácido cafeico, usos terapêuticos e cosméticos
AR061171A1 (es) Proteinas de union al factor de crecimiento de hepatocitos (fch)
BRPI1011710B8 (pt) composição para ser usada como uma lágrima artificial
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
PA8780101A1 (es) Imidazopiridazina y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
AR061170A1 (es) Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
DOP2008000018A (es) Anticuerpos anti-ige
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
BRPI1000320B8 (pt) Composições e métodos para tratar sinais de envelhecimento da pele
BR112013023970A2 (pt) composição farmacêutica, dispositivo, inibidor de hdac, kit, método de pré-tratamento de um ser humano que sofre de câncer e método de avaliação do efeito de uma substância sobre a sensibilidade a chop de linhagens celulares
BRPI0803568B8 (pt) composição mucoaderente
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
BR112015024920A2 (pt) associação sinérgica da alanina-glutamina, o ácido hialurônico e um extrato de aveia e sua utilização em uma composição destinada à cicatrização e o reparo das lesões cutâneas
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
BR112016015641A2 (pt) Composições e métodos de tratamento de condições patológicas inflamatórias da pele usando alantoína

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B25A Requested transfer of rights approved

Owner name: MESOBLAST INTERNATIONAL SARL (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 35/28 (2015.01), C12N 5/0775 (2010.01), A61K

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]